Form 4: TriSalus Life Sciences Executive Richard Marshak Reports Acquisition and Disposal of Common Stock

Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, reports the acquisition of 7,644 shares of common stock and disposal of shares on February 18, 2025, according to a Form 4 filing.

Summary

• Richard Marshak, the Chief Commercial Officer of TriSalus Life Sciences, filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on February 18, 2025.
• Marshak acquired 7,644 shares of common stock at $0 and disposed of 54,270 shares.
• Following the reported transaction, Marshak beneficially owns 54,270 shares of common stock.
• The filing also details the grant of restricted stock units (RSU Award) payable in common stock of the Issuer.
• 12.5% of the shares subject to the RSU Award shall vest on the grant date of February 18, 2025; 25% of the shares subject to the RSU Award shall vest on each of May 15, 2025, August 15, 2025, and November 14, 2025; and the remaining shares subject to the RSU Award will vest on February 13, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but the granting of RSUs is generally a positive sign for employee retention and alignment with company goals.

Positives

• The grant of restricted stock units to the Chief Commercial Officer aligns his interests with the long-term success of the company.

Future Outlook

The vesting schedule of the restricted stock units incentivizes the Chief Commercial Officer to remain with the company and contribute to its growth over the next year.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the compensation structure for a key executive at TriSalus Life Sciences.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive incentive for the Chief Commercial Officer.
• Employees may see the RSU grant as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Form 4, TriSalus Life Sciences, Richard Marshak, stock, acquisition, disposal, restricted stock units, TLSI, Chief Commercial Officer